Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study

J Natl Cancer Inst. 1991 Sep 4;83(17):1250-2. doi: 10.1093/jnci/83.17.1250.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Female
  • Humans
  • Injections, Intravenous
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use*
  • Male
  • Melanoma / drug therapy*
  • Middle Aged
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use

Substances

  • Interleukin-2
  • Recombinant Proteins